Lumicell Expands Development Strategy and Pipeline Across Five Solid Tumor Cancers Supported by $28.7 Million Series C Financing Proceeds to Fund Pivotal Trial in Breast Cancer

Lumicell, Inc., a technology leader in the field of image-guided cancer surgery, today provided an update on the company’s development strategy for its LUM system pipeline including plans to initiate its pivotal trial in breast cancer as well as expansion of its clinical studies in four other solid tumor cancers.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *